Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 17/20 | 0.59 |
| ▸ | PDE4A | P27815 | 1/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.59 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8349381 | 0.92 | PDE4B (0.70) | PDE4BPDE4APDE4DPTGER4CYP3A4 | |
| SCHEMBL5203750 | 0.92 | PDE4B (0.70) | PDE4BPDE4APDE4DPTGER4CYP3A4 | |
| SCHEMBL6063525 | 0.89 | PDE4B (0.58) | PDE4BPDE4APDE4DPTGER4 | |
| SCHEMBL8295429 | 0.88 | PDE4B (0.58) | PDE4BPDE4APDE4DPTGER4CYP3A4 | |
| SCHEMBL8354237 | 0.86 | PDE4B (0.61) | PDE4BPDE4APDE4DCYP3A4SCN9A | |
| Hydrochloric Acid SCHEMBL6063601 | 0.85 | PDE4B (0.61) | PDE4BPDE4APDE4DCYP3A4SCN9A | |
| SCHEMBL6063303 | 0.84 | PDE4B (0.53) | PDE4BPDE4APDE4DPTGER4CYP3A4 | |
| SCHEMBL8353996 | 0.84 | PDE4B (0.53) | PDE4BPDE4APDE4DPTGER4CYP3A4 | |
| SCHEMBL5839521 | 0.82 | PDE4B (0.51) | PDE4BPDE4APDE4DCYP3A4 | |
| SCHEMBL5841990 | 0.82 | PDE4B (0.51) | PDE4BPDE4APDE4DCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7060717-B2 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC (US) | 2006-06-13 | — | — | US | disclosed |
| US-20060014780-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC | 2006-01-19 | — | — | US | disclosed |
| US-6949573-B2 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC (US) | 2005-09-27 | — | — | US | disclosed |
| EP-1069107-B1 | FULLERENE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-05-11 | — | — | EP | disclosed |
| US-20040224975-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. | 2004-11-11 | — | — | US | disclosed |
| US-20040214218-A1 | Fullerene derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-10-28 | — | — | US | disclosed |
| US-6765098-B1 | DNA COMPACTION; GENE THERAPY | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-07-20 | — | — | US | disclosed |
| US-20030220361-A1 | Administering together tiotropium salt and substituted 3-amidopyridine derivatives for treating inflammation, allergic and respiratory diseases | PFIZER INC. | 2003-11-27 | — | — | US | disclosed |
| US-20030220366-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003068233-A1 | NICOTINAMIDE DERIVATIVES AND A TIOTROPIUM SALT IN COMBINATION FOR THE TREATMENT OF E.G. INFLAMMATORY, ALLERGIC AND RESPIRATORY DISEASES | PFIZER LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003068235-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| EP-1069107-A1 | FULLERENE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214218-A1 | Fullerene derivatives | RCC1, TOP2A, DNAH12 | PDE4B 3890/4885PDE4A 4068/4885PDE4D 4023/4885 |
| US-20060014780-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4A 1/4885PDE4D 5/4885 |
| US-20030220361-A1 | Administering together tiotropium salt and substituted 3-amidopyridine derivatives for treating inflammation, allergic and respiratory diseases | NNT, IL5, NOX5 | PDE4B 74/4885PDE4A 69/4885PDE4D 271/4885 |
| US-20040224975-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4A 1/4885PDE4D 5/4885 |
| US-20030220366-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4A 1/4885PDE4D 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.